I agree that this site is using cookies. You can find further informations here.
X
Socinski, M
~ 100  results:
Search for persons X
?
1

A phase I study to evaluate the safety, pharmacokinetics, a..:

Rodon, J. ; Rodriguez, E. ; Maitland, M.L....
ESMO Open.  9 (2024)  4 - p. 102961 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Predictive biomarkers for response to EGFR-directed monoclo..:

Bonomi, P.D. ; Gandara, D. ; Hirsch, F.R....
Annals of Oncology.  29 (2018)  8 - p. 1701-1709 , 2018
Link: https://doi.org/10.1093/..
 
?
3

Heart Dosimetric Analysis of Three Types of Cardiac Toxicit..:

Wang, K. ; Pearlstein, K.A. ; Patchett, N.D....
International Journal of Radiation Oncology*Biology*Physics.  99 (2017)  2 - p. S152 , 2017
Link: https://doi.org/10.1016/..
 
?
4

Results of a Single-Institution Experience With Dose-Escala..:

Bernard, M. ; Glaser, S.M. ; Gill, B.S....
International Journal of Radiation Oncology*Biology*Physics.  96 (2016)  2 - p. E449 , 2016
Link: https://doi.org/10.1016/..
 
?
5

The Effect of Necitumumab in Combination with Gemcitabine-C..:

Reck, M ; Socinski, M ; Szczesna, A...
Value in Health.  19 (2016)  7 - p. A748-A749 , 2016
Link: https://doi.org/10.1016/..
 
?
6

Correlation of EGFR-expression with safety and efficacy out..:

Paz-Ares, L. ; Socinski, M.A. ; Shahidi, J....
Annals of Oncology.  27 (2016)  8 - p. 1573-1579 , 2016
Link: https://doi.org/10.1093/..
 
?
7

3109 nab-Paclitaxel (nab-P) plus carboplatin (C) as first-l..:

Gridelli, C. ; Li, L. ; O'Brien, M....
European Journal of Cancer.  51 (2015)  - p. S638-S639 , 2015
Link: https://doi.org/10.1016/..
 
?
8

3073 Exploratory analysis of frontline therapies in REVEL: ..:

Garon, E.B. ; Scagliotti, G.V. ; Gautschi, O....
European Journal of Cancer.  51 (2015)  - p. S621 , 2015
Link: https://doi.org/10.1016/..
 
?
9

3009 Activity of rociletinib in EGFR mutant NSCLC patients ..:

Varga, A. ; Camidge, D.R. ; Sequist, L.V....
European Journal of Cancer.  51 (2015)  - p. S598 , 2015
Link: https://doi.org/10.1016/..
 
?
10

Erlotinib in African Americans With Advanced Non–Small Cell..:

Phelps, M A ; Stinchcombe, T E ; Blachly, J S...
Clinical Pharmacology & Therapeutics.  96 (2014)  2 - p. 182-191 , 2014
Link: https://doi.org/10.1038/..
 
?
11

Update on Taxanes in the First-Line Treatment of Advanced N..:

Socinski, M.A.
Current Oncology.  21 (2014)  5 - p. 691-703 , 2014
Link: https://doi.org/10.3747/..
 
?
12

41 Clinical activity of BIND-014 (docetaxel nanoparticles f..:

Natale, R. ; Socinski, M. ; Hart, L....
European Journal of Cancer.  50 (2014)  - p. 19 , 2014
Link: https://doi.org/10.1016/..
 
?
13

Analysis of Outcomes in Diabetic Patients in a Phase 3 Tria..:

Hirsh, V. ; Owen, S.P. ; Ko, A...
International Journal of Radiation Oncology*Biology*Physics.  90 (2014)  5 - p. S21 , 2014
Link: https://doi.org/10.1016/..
 
?
14

Switch Maintenance With Sunitinib (S) in Advanced Non-Small..:

Socinski, M.A. ; Wang, X. ; Baggstrom, M....
International Journal of Radiation Oncology*Biology*Physics.  90 (2014)  5 - p. S1 , 2014
Link: https://doi.org/10.1016/..
 
?
15

Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlot..:

Gerber, D.E. ; Socinski, M.A. ; Neal, J.W....
International Journal of Radiation Oncology*Biology*Physics.  90 (2014)  5 - p. S36 , 2014
Link: https://doi.org/10.1016/..
 
1-15